ASP7962

Phase 2Small molecule

Astellas

ASP7962 is one of 24 small molecule programs targeting Osteoarthritis. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

OsteoarthritisActive, not recruiting

OsteoarthritisPhase 2

Active, not recruiting

Competition

Competitive Landscape

778 competitors in Osteoarthritis

#DrugCompanyPhaseTrials

Toradol

Roche

Preclinical

1 2

Cataflam

Platelet Rich Plasma

25 4

Voltaren

CCerimon Pharmaceuticals

Preclinical

4 5

Enbrel

IImmunex

Preclinical

2 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 7

Protonix

WWyeth-Lederle Vaccines

Preclinical

1 8

Paracetamol

GSK

Preclinical

4 9

Naproxen Sodium

Bayer

Preclinical

1 10

Decadron

QQuince Therapeutics S.p.A.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Clinical Trial1 trial

A Clinical Trial to Investigate Safety and Tolerability of ASP7962 in Healthy Humans

Completed· Astellas logo

Astellas·Phase 1·NCT01981928·48 enrolled

Tics1 trial

A Study to Assess the Safety, Tolerability and Pharmacokinetics (PK) of Multiple Ascending Doses of ASP7962 in Healthy Subjects

Completed· Astellas logo

Astellas·Phase 1·NCT02136316·48 enrolled

Osteoarthritis1 trial

A Study to Assess the Analgesic Efficacy of ASP7962 in Patients With Pain Due to Osteoarthritis of the Knee

Completed· Astellas logo

Astellas·Phase 2·NCT02611466·215 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for ASP7962. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ASP7962 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ASP7962. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Astellas company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Astellas

ASP7962

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Clinical Trial1 trial

Tics1 trial

Osteoarthritis1 trial

References

Drug Info

Quick Facts

Related News